A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

NCT ID: NCT04179500

Last Updated: 2025-01-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-16
• Study Completion Date: 2024-07-17

Brief Summary

Pretomanid is being used in an antimicrobial combination regimen(s) to treat patients with pulmonary tuberculosis (TB). The primary purpose of the Male Reproductive Safety - "BPaMZ/SEM"- clinical study is to evaluate the potential effect of pretomanid on human testicular function whilst being used in a 26 weeks antimicrobial combination regimen consisting of bedaquiline (B) plus pretomanid (Pa) plus moxifloxacin (M) and pyrazinamide (Z) (BPaMZ).

Detailed Description

The primary objective of this study is to assess the male reproductive safety of pretomanid in the regimen (BPaMZ) of bedaquiline 200mg (200mg daily for 8 weeks then 100 mg daily for 18 weeks), together with pretomanid 200 mg (1x daily) + moxifloxacin 400 mg (1x daily) + pyrazinamide 1500 mg (1 x daily) for 26 weeks in participants with drug-resistant pulmonary tuberculosis (DR-TB).

The secondary objective of the study is to evaluate the tuberculosis (TB) treatment efficacy, safety and tolerability after 26 weeks of active treatment for TB and follow up until 52 weeks after end of the above-described treatment regimen in participants with DR-TB.

Conditions

Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR; Tuberculosis; Drug-Resistant Tuberculosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Study Participants

Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.

Group Type: EXPERIMENTAL

Pretomanid

Intervention Type: DRUG

pretomanid 200 mg (once daily) for 26 weeks (with meal)

Bedaquiline

Intervention Type: DRUG

bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)

moxifloxacin

Intervention Type: DRUG

moxifloxacin 400 mg (once daily) for 26 weeks (with meal)

pyrazinamide

Intervention Type: DRUG

pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)

Interventions

Pretomanid

pretomanid 200 mg (once daily) for 26 weeks (with meal)

Intervention Type: DRUG

Bedaquiline

bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)

Intervention Type: DRUG

moxifloxacin

moxifloxacin 400 mg (once daily) for 26 weeks (with meal)

Intervention Type: DRUG

pyrazinamide

pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)

Intervention Type: DRUG

Other Intervention Names

Pa-824; Doprevla; Pa; Sirturo; B; Avelox; M; Pyzina; Tebrazid; Z

Eligibility Criteria

Inclusion Criteria

1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures.

2. Male gender 18 years or over

3. Body weight (in light clothing and no shoes) ≥ 45kg.

4. A positive molecular test for tuberculosis in sputum either at screening or within one month prior to enrolment.

5. Disease Characteristics:

• Participants must have been diagnosed with TB prior to or at screening
• Participants' TB should be resistant to rifampicin and/or isoniazid, and susceptible to fluoroquinolones by rapid sputum-based tests.
• Participants who have had previous treatment for DR-TB for more than 3 months at start of screening should be discussed with the medical monitor.

6. A chest x-ray, within 26 weeks prior to or at the screening visit, which in the opinion of the Investigator is compatible with pulmonary TB

Exclusion Criteria

1. Resistant to fluoroquinolones by rapid molecular test

2. History of male infertility or vasectomy

3. Unable to produce semen sample

4. Evidence at screening of azoospermia

5. Known erectile dysfunction that would prevent ejaculation.

6. Historical or active disease process of the male reproductive tract that would compromise sperm production. e.g. tuberculous epididymitis.

7. History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.

8. For HIV infected participants any of the following:

1. CD4+ count <100 cells/μL

2. Received intravenous antifungal medication within the last 90 days

9. Participants with newly diagnosed tuberculosis and HIV that require initiation of appropriate HIV therapy before participants has received at least 2 weeks of an antituberculosis regimen.

10. Received pretomanid and/or delamanid to treat TB

11. Known chronic hepatitis B or C

12. For HIV infected participants:

1. The following antiretroviral therapy (ART) should not be used:

1. Stavudine 2. Zidovudine 3. Didanosine 4. Triple NRTI regimen is not considered optimal for HIV treatment (poor efficacy)

13. Participants with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table (Draft November 2007) where applicable:

1. Platelets <75,000/mm3

2. Creatinine >1.5 times upper limit of normal (ULN)

3. eGFR ≤ 60 mL/min

4. Haemoglobin <8.0 g/dL

5. Serum potassium less than the lower limit of normal for the laboratory. This may be repeated once

6. AST:

• ≥3.0 x ULN to be excluded
• results between 1.5 x ULN and 3 x ULN must be discussed with and approved by the Sponsor Medical Monitor

7. ALT:

• ≥3.0 x ULN to be excluded
• greater than ULN must be discussed with and approved by the Sponsor Medical Monitor

8. ALP:

• ≥3.0 x ULN to be excluded
• 2.0 - <3.0 x ULN must be discussed with and approved by the Sponsor Medical Monitor

9. Total bilirubin:

• >1.5 x ULN to be excluded
• Greater than ULN must be discussed with and approved by the Sponsor Medical Monitor

10. Direct bilirubin:

• greater than 1x ULN to be excluded

11. Positive hepatitis B surface Ag, or hepatitis C antibody

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Global Alliance for TB Drug Development

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Antonio Lombardi, MD

Role: STUDY_CHAIR

Global Alliance for TB Drug Development

Locations

National Center for Tuberculosis and Lung Diseases

Tbilisi, , Georgia

CHRU, Sizwe Tropical Diseases Hospital

Johannesburg, , South Africa

Isango Lethemba TB Research Unit Empilweni TB Hospital

Port Elizabeth, , South Africa

The Aurum Institute: Rustenburg Clinical Research Centre

Rustenburg, , South Africa

Countries

Georgia; South Africa

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Pa-824-CL-012

Identifier Type: -

Identifier Source: org_study_id